Patents Issued in March 6, 2001
  • Patent number: 6197499
    Abstract: The present invention relates to a method of detecting a DNA sequence by means of a DNA:DNA hybrid in real time using fluorescence. The present invention eliminates the need to use radioactive probes to detect the DNA and eliminates the delay needed for autoradiographic exposure of the X-ray to the radioactive label.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: March 6, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stephen H. Hughes, Ramesh Kumar, John Brumbaugh
  • Patent number: 6197500
    Abstract: The DNA sequence spanning the fragile X site on the X human chromosome has been obtained in purified and isolated form. As fragile X is associated with mental retardation, the availability of a DNA which spans this locus permits diagnosis and treatment of the related mental disorders.
    Type: Grant
    Filed: September 9, 1993
    Date of Patent: March 6, 2001
    Assignee: Adelaide Medical Centre for Women and Children
    Inventors: Grant R. Sutherland, Robert I. Richards, David Schlessinger, Ramaiah Nagaraja, Eric J. Kremer, Sui Yu, Elizabeth Baker, John C. Mulley, Jean-Louis Mandel, Melanie April Pritchard, Michael Lynch
  • Patent number: 6197501
    Abstract: A method of determining the relative number of nucleic acid sequences in test cells which provides for a high resolution during comparative genomic hybridization by keeping all components separate from each other and selecting target nucleic acids which have a high resolution capability for determining genomic imbalances in the test cells and which facilitate a screening of the test cells for over- or under-expression of individual genes.
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: March 6, 2001
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Thomas Cremer, Thomas Ried, Michael Speicher, Anna Jauch, Peter Lichter
  • Patent number: 6197502
    Abstract: The present invention is directed to a method for detection, characterization and isolation of nucleic acids encoding proteins of a desired property, such as a particular cellular localization. The invention further provides for rapid expression of such proteins or glycoproteins in mammalian cells and for facilitated purification of the novel secreted proteins or glycoproteins. Further, the invention provides for radioactive labelling of the novel proteins or glycoproteins, for rapid identification of sites of binding including animals and for rapid production of infective viral vectors for use in gene transfer.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: March 6, 2001
    Assignee: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Georg H. Orberger, Daniel Koller, James E. Bailey
  • Patent number: 6197503
    Abstract: The present invention discloses a self-contained miniature DNA biosensor designed to detect specific molecular targets, particularly suitable for detection of nucleic acids. For example, hybridized DNA may be detected without external monitoring or signal transmission. The miniaturized biosensor is a biochip comprising multiple biological sensing elements such as DNA probes, excitation microlasers, a sampling waveguide equipped with optical detectors (fluorescence and Raman), integrated electrooptics, and a biotelemetric radio frequency signal generator. The novel integrated circuit biochip microsystem (ICBM) is suitable for gene analysis and will allow rapid, large-scale, and cost-effective production of gene biochips.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: March 6, 2001
    Assignee: UT-Battelle, LLC
    Inventors: Tuan Vo-Dinh, Alan Wintenberg, Milton N. Ericson
  • Patent number: 6197504
    Abstract: This invention provides vectors comprising isolated polynucleotides comprising a member selected from the group consisting of: (a) a polynucleotide encoding MAB-21 protein; (b) a polynucleotide capable of hybridizing to and which is at least 60% identical to the polynucleotide of (a); and (c) a polynucleotide fragment of the polynucleotide of (a) or (b). This invention further provides host-vectors system for the expression of MAB-21 protein and protein products of mab-21 homologs. This invention further provides MAB-21 protein and protein products of mab-21 homologs. This invention also provides antibodies capable of specifically binding to the MAB-21 protein or protein products of mab-21 homologs. Finally, this invention also provides methods for identifying various suppressor, enhancer and modifier genes of the mab-21 and its homologs.
    Type: Grant
    Filed: January 19, 1998
    Date of Patent: March 6, 2001
    Inventor: King Lau Chow
  • Patent number: 6197505
    Abstract: The present invention provides methods for assessing cardiovascular status in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding angiotensin converting enzyme (ACE), angiotensinogen (AGT), and/or type 1 angiotensin II receptor (AT1). The invention also provides isolated nucleic acids encoding ACE, AGT, and AT1 polymorphisms, nucleic acid probes that hybridize to polymorphic positions, kits for the prediction of cardiovascular status, and nucleic acid and peptide targets for use in identifying candidate cardiovascular drugs.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: March 6, 2001
    Assignee: Pyrosequencing AB
    Inventors: Leif Torbjörn Norberg, Maria Kristina Andersson, Per Harry Rutger Lindström
  • Patent number: 6197506
    Abstract: The present invention provides methods and apparatus for sequencing, fingerprinting and mapping biological macromolecules, typically biological polymers. The methods make use of a plurality of sequence specific recognition reagents which can also be used for classification of biological samples, and to characterize their sources.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: March 6, 2001
    Assignee: Affymetrix, Inc.
    Inventors: Stephen P. A. Fodor, Dennis W. Solas, William J. Dower
  • Patent number: 6197507
    Abstract: A method for diagnosing or screening for bovine &agr;-mannosidosis comprises detecting in nucleic acid samples from cattle the presence or absence of &agr;-mannosidosis-causing mutations in the gene encoding bovine lysosomal &agr;-mannosidase (LAMAN). A method of detecting &agr;-mannosidosis-causing mutations in cattle comprises detecting the presence or absence of base transitions in the gene encoding bovine LAMAN which are associated with the disease.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: March 6, 2001
    Inventors: Thomas Berg, Ole Kristien Tollersrud, Oivind Nilssen
  • Patent number: 6197508
    Abstract: A process is described for denaturing native double-stranded nucleic acid material into its individual strands in an electrochemical cell. The process disclosed is an electrical treatment of the nucleic acid with a voltage applied to the nucleic acid material by an electrode. The process may also employ a promoter compound such as methyl viologen to speed denaturation. The process may be used in the detection of nucleic acid by hybridizing with a labelled probe or in the amplification of DNA by a polymerase chain reaction or ligase chain reaction. A process is described for annealing complementary strands of nucleic acid by application of an electrical voltage.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: March 6, 2001
    Assignee: Affymetrix, Inc.
    Inventor: Christopher J. Stanley
  • Patent number: 6197509
    Abstract: A novel, highly polymorphic DNA marker based on the pentanucleotide repeat (CCTTT/GGAAA)n has been identified in the human inducible nitric oxide synthase (iNOS) gene. Twelve different alleles, having between 7 and 18 repeats, have been identified. The repeat is highly polymorphic in the human population and so lends itself to use as a microsatellite marker with uses in, for example, forensic medicine, population studies, family linkage studies and disease diagnosis.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: March 6, 2001
    Assignee: Medical Research Council
    Inventor: Weiming Xu
  • Patent number: 6197510
    Abstract: The invention provides a method of sequencing a nucleic acid in a reaction mixture comprising first and second nucleic acid target sequences. The target sequences may be present on the same or different nucleic acid molecules. First and second labelled sequencing primers are provided that are hybridizable, respectively, to the first and second nucleic acid target sequences. The second sequencing primer being at least as long as the total length of the first sequencing primer plus the length of the first target sequence. Each of the sequencing primer extension products beginning with the second sequencing primer will be longer than the primer extension products in the pool beginning with the first sequencing primer. Once the sequencing reactions have been completed, the lengths of the primer extension products in the pool may be detected by known methods, such as by gel electrophoresis.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: March 6, 2001
    Assignee: Bio-Id Diagnostic Inc.
    Inventor: Thuraiayah Vinayagamoorthy
  • Patent number: 6197511
    Abstract: The present invention provides a human tumor suppressor (HKALL) and polynucleotides which identify and encode HKAL,. The invention also provides expression vectors and host cells, agonists, antibodies, or antagonists. The invention provides methods for treating diseases associated with expression of HKALL.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: March 6, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal
  • Patent number: 6197512
    Abstract: The invention provides human myosin heavy chain-like proteins (MHCP) and polynucleotides which identify and encode MHCP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating disorders associated with expression of MHCP.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: March 6, 2001
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Henry Yue, Neil C. Corley, Purvi Shah
  • Patent number: 6197513
    Abstract: Disclosed herein are methods for linking a protein or other biomolecule containing a carboxylic acid moiety to a PNA or DNA probe molecule. The methods disclosed herein involve activating the carboxylic acid moiety with an activating agent and reacting the activated carboxylic acid moiety with a PNA or DNA probe having an arylamine or aminooxyacetyl moiety. Conjugates produced by these methods are also disclosed.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: March 6, 2001
    Assignee: PE Corporation
    Inventors: James Coull, Richard Fitzpatrick
  • Patent number: 6197514
    Abstract: Amplification primers and methods for specific amplification and detection of a Yersinia enterocolitica target are disclosed. The primer-target binding sequences are useful for amplification and detection of Y. enterocolitica target in a variety of amplification and detection reactions.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: March 6, 2001
    Assignee: Becton, Dickinson and Company
    Inventors: Qimin You, Thomas L. Fort
  • Patent number: 6197515
    Abstract: An article suitable for use as a biosensor includes a molecule of a formula X—R—Ch adhered to a surface of the article as part of a self-assembled monolayer. X is a functionality that adheres to the surface, R is a spacer moiety, and Ch is a chelating agent. A metal ion can be coordinated by the chelating agent, and a polyamino acid-tagged biological binding partner of a target biological molecule coordinated to the metal ion. A method of the invention involves bringing the article into contact with a medium containing or suspected of containing the target biological molecule and allowing the biological molecule to biologically bind to the binding partner. The article is useful particularly as a surface plasmon resonance chip.
    Type: Grant
    Filed: April 21, 1999
    Date of Patent: March 6, 2001
    Assignee: Harvard University
    Inventors: Cynthia C. Bamdad, George B. Sigal, Jack L. Strominger, George M. Whitesides
  • Patent number: 6197516
    Abstract: The present invention provides a computer method and apparatus for detecting mutations in DNA fragments. Specifically, percent acetonitrile and threshold temperature, for use in the denaturing high performance liquid chromatography method of separating DNA fragments, are determined. In a preferred embodiment, the present invention serves as a preprocessor to the DHPLC system described in the cited art.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: March 6, 2001
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David Altshuler, Eric S. Lander
  • Patent number: 6197517
    Abstract: The present invention relates to genes in Saccharomyces cerevisiae which are essential for germination and proliferation of S. cerevisiae and using the identified genes or their encoded proteins as targets for highly specific antifungal agents, insecticides, herbicides and anti-proliferation drugs. The present invention provides antisense molecules and ribozymes comprising sequences complementary to the sequences of mRNAs of essential genes that function to inhibit the essential genes. The present invention also provides neutralizing antibodies to proteins encoded by essential genes that bind to and inactivate the essential gene products. The present invention further provides pharmaceutical compositions for treating fungal and proliferative diseases, as well as methods of treatment of fungal and proliferative diseases.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: March 6, 2001
    Assignee: Rosetta Inpharmatics, Inc.
    Inventor: Christopher J. Roberts
  • Patent number: 6197518
    Abstract: The chromosomal location of Fusarium head blight (FHB) resistance genes in wheat and the discovery of molecular markers for detecting the presence of these genes is herein described. The markers are generated via PCR or similar amplification reaction using primers identified herein. As a result, seed material can be assayed, thereby eliminating the time and cost involved in assaying adult plants for FHB resistance. Furthermore, the markers allow for gene pyramiding of the multiple, independent resistance genes into complex genetic backgrounds. In addition, the markers can be assayed in parallel. Finally, the markers are cost effective, highly reliable and accurate, and require just a few hours for testing.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: March 6, 2001
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Department of Agriculture
    Inventors: James Douglas Procunier, Jeannie Gilbert, T. Fred Townley-Smith, Ken Armstrong, George Fedak
  • Patent number: 6197519
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: March 6, 2001
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Scott Michael Braxton, Craig G. Wilde, Dinh Diep
  • Patent number: 6197520
    Abstract: The present invention is directed to a method of analyzing at least two analytes at the same time using at least two fluorescent detecting entities. More particularly, the present invention relates to the use of fluorescently labeled hybridization probes to identify the genotypes of a nucleic acid sample at more than one locus by measuring fluorescence throughout a range of temperatures and correcting for temperature-dependent spectral overlap of the fluorescent probes.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: March 6, 2001
    Assignee: University of Utah Research Foundation
    Inventors: Carl T. Wittwer, Gregory Pritham, Philip Bernard
  • Patent number: 6197521
    Abstract: The invention provides genetic suppressor elements that confer the transformed phenotype of malignant mammalian cells upon untransformed cells, methods for identifying and obtaining such elements, methods for isolating and identifying genes corresponding to such elements, and methods of using such elements. The invention also provides genes corresponding to the GSEs of the invention.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: March 6, 2001
    Assignee: University of Illinois
    Inventors: Andrei Gudkov, Alexander Kazarov, Ilya Mazo, Igor B. Roninson
  • Patent number: 6197522
    Abstract: Disclosed is a method for quantitatively identifying polymers in an aqueous system using immunoassay techniques, wherein at least a portion of the polymers contain a detectable terminus. This is particularly useful in water treatment systems. Also disclosed are new hybridoma cell lines which express MAbs which specifically recognize such a detectable terminus.
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: March 6, 2001
    Assignee: Rohm and Haas Company
    Inventors: Lorraine Holowach Keller, Barry Weinstein
  • Patent number: 6197523
    Abstract: A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence or absence of target cancer cells and/or hematologic progenitor cells which are known to circulate in blood. The analysis is performed in a sample of centrifuged anticoagulated whole blood. The analysis involves both morphometric and epitopic examination of the blood sample while the blood sample is disposed in a centrifuged blood sampling tube. The epitopic analysis of the presence or absence of cancer cells relies on the detection of epitopes which are known to present only on cancer cells; and the epitopic analysis of the presence or absence of hematologic progenitor cells relies on the detection of epitopes which are known to present only on hematologic progenitor cells.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: March 6, 2001
    Inventors: David L. Rimm, Robert A. Levine, Stephen C. Wardlaw, Paul Fiedler
  • Patent number: 6197524
    Abstract: The lymphocyte ativation gene (LAG-3) is a member of the immunoglobulin superfamily that is selectively transcribed in human activated T and NK cells. Surface LAG-3 expression correlated with IFN-&ggr; but not IL-4, production in antigen-stimulated T-cells and it was up-regulated by IL-12 and is preferentially associated with CD4+ T-cells producing Th1-type cytokines. The presence of LAG-3 on the surface of Th1 lymphocytes is used as a marker to detect and identify Th1 lymphocytes and differentiate them from Th2 lymphocytes. Monoclonal antibodies to LAG-3 are used in methods of detecting and isolating Th1 cells as well as methods of diagnosing Th1-mediated disease. The present invention also relates to methods of treating infectious diseases, cancer, and disorders assocated with Th1/Th2 imbalance.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: March 6, 2001
    Assignees: Institute National de la Sante et de la Recherche Medicale, Institut Gustave Roussy, Applied Research Systems, ARS Holding N.V.
    Inventor: Sergio Romagnani
  • Patent number: 6197525
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, pharmaceutical compositions made therefrom, detection assays and methods of inhibiting binding of the receports are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: March 6, 2001
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Patent number: 6197526
    Abstract: Methods for detecting human factor VIII or factor VIII-like polypeptides in and isolating it from solutions such as blood or conditioned media are disclosed, together with reagents suitable for the purpose comprising binding moieties that recognize human factor VIII and/or a factor VIII-like polypeptide and form a binding complex therewith. Preferred polypeptide binding moieties are particularly disclosed.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: March 6, 2001
    Assignees: Dyax Corp., Genetics Inst.
    Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James Edward Booth
  • Patent number: 6197527
    Abstract: This invention provides novel assays for topoisomerase activity and for identifying topoisomerase inhibitors. The assays include both solid-phase and liquid-phase methods that are amenable to high throughput screening methods. The assays of the invention are readily adaptable to numerous types of topoisomerase, and are capable of identifying novel classes of topoisomerase activity modulators.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: March 6, 2001
    Assignee: Tularik Inc.
    Inventors: Anthony Simon Lynch, Binoj Joseph Matthew
  • Patent number: 6197528
    Abstract: The present invention relates to compositions of retinoids plus immunotoxins. More particularly this invention relates to the use of retinoids to potentiate the activity of immunotoxins for treatment of mammalian diseases.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: March 6, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: YouNeng Wu, Richard J. Youle
  • Patent number: 6197529
    Abstract: Linear substituted oligoalkyleneimine molecules and libraries of molecules are disclosed, as are their methods of synthesis and use in acceptor binding assays. Each molecule or chain of a library contains the same number of 2 to about 10 substituted alkyleneimine repeating units, whose substituents are reduced amino acid side chains bonded to the repeating units at a position alpha to the nitrogen atom, and the member chains of a library are present in equimolar amounts. The chains of a library contain one or more predetermined reduced amino acid side chain-substituted repeating units at one or more predetermined positions of the substituted oligoalkyleneimine chain. The library contains equimolar amounts of at least six different reduced amino acid side chain-substituted repeating units at one or more of the same predetermined positions of the substituted oligoalkyleneimine chain. Particularly preferred linear substituted oligoalkyleneimine molecules and libraries are linear substituted oligoethyleneimines.
    Type: Grant
    Filed: May 18, 1993
    Date of Patent: March 6, 2001
    Assignee: Torrey Pines Institute for Molecular Studies
    Inventors: Richard A. Houghten, Julio Hernan Cuervo, Fred F. Weitl
  • Patent number: 6197530
    Abstract: The invention features assays for the identification of compounds useful for the modulation of body weight. Such compounds are useful for the treatment of obesity and cachexia. The methods of the invention involve cell-free and cell-based assays that identify compounds which bind to and/or activate or inhibit the activity of GPR10, a G protein-coupled receptor, followed by an in vivo assay of the effect of the compound on feeding behavior, body weight, or metabolic rate. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR10 as well as pharmaceutical compositions comprising such compounds. In addition, the invention includes nucleic acid molecules comprising a nucleotide sequence encoding all or a portion of murine GPR10, polypeptides comprising all or a portion of murine GPR10, antibodies directed against murine GPR10, and animals harboring a murine GPR10 transgene (e.g., mice overexpressing murine GPR10).
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: March 6, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Alain Stricker-Krongrad, Wei Gu
  • Patent number: 6197531
    Abstract: A method for determining the immunocompetence of a mammal is described. Bodily fluid having T cell receptor complexes from a mammal is provided. Expression of a first component and a second component of the T cell receptor complexes is evaluated. An abnormal ratio of the number of cells expressing the first component as compared to the number of cells expressing the second component indicates altered immunocompetence in the mammal.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: March 6, 2001
    Assignee: Center For Blood Research, Inc.
    Inventor: Judy Lieberman
  • Patent number: 6197532
    Abstract: Measurements of elevated levels of riboflavin carrier protein (RCP) can be used to detect breast, liver, ovarian, and endometrial cancers. Stains for riboflavin carrier protein can be used to visualize malignancies in tissue specimens. The new technique is particularly well-suited for the early detection of breast cancer. With a radioimmunoassay for RCP, we have observed that serum RCP levels were significantly elevated in women with breast cancer as compared to control subjects. A serum RCP level ≧1.0 ng/ml was highly predictive of the presence of breast cancer (other than in pregnant females).
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: March 6, 2001
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Prakash N. Rao, Madhwa H. G. Raj
  • Patent number: 6197533
    Abstract: There is described a method for the chemical modification of antibodies and/or antigens in order to minimise sample interference in immunoassays, an immunoassay method in which chemically modified antibodies and/or antigens are employed, the use of chemically modified antibodies and/or antigens in an immunoassay and a kit for assaying biological specimens which comprises the chemically modified antibodies and/or antigens.
    Type: Grant
    Filed: February 10, 1995
    Date of Patent: March 6, 2001
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Adrian Charles Dawkes, John Arthur Diment, Graham DeLisle Yearwood
  • Patent number: 6197534
    Abstract: Disclosed are methods and sensors for detecting the presence or concentration of an analyte in a sample, preferably a sugar such as glucose, which preferably utilizes a labeled engineered protein, or fragment thereof, that is capable of binding the analyte to be detected.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: March 6, 2001
    Inventors: Joseph R. Lakowicz, Leah Tolosa, Lisa Eichhorn, Govind Rao
  • Patent number: 6197535
    Abstract: The present invention is relates to a method for purifying a &ggr;-carboxylase from Conus snails and to a method for assaying the activity of this &ggr;-glutamyl carboxylase.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: March 6, 2001
    Assignee: University of Utah Research Foundation
    Inventors: Pradip K. Bandyopadhyay, Craig S. Walker, Baldomero M. Olivera
  • Patent number: 6197536
    Abstract: The process according to the present invention allows expression and isolation of polypeptides with the proteolytic activity of HCV NS3 protease in a pure, catalytically active form, and in amounts that are sufficient for discovery of NS3 protease inhibitors and for determination of the three-dimensional structure of the NS3 protease. A further subject of the present invention is a procedure that defines the chemical and physical conditions necessary for completion of the proteolytic activity of the above polypeptides. The invention further comprises new compositions of matter (expression vectors) containing nucleotide sequences capable of expressing the above mentioned polypeptides in culture cells. Finally, new compounds of matter are defined, suitable to measure the above proteolytic activity, and useful to develop NS3 protease inhibitors and therefore therapeutic agents for use against HCV. The figure shows the kinetic parameters of HCV NS3 protease using the S3 depsipeptide substrate (SEQ ID NO:45).
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: March 6, 2001
    Assignee: Istituto di Ricerche di Biologia Moleculare S.p.A.
    Inventors: Christian Steinkühler, Antonello Pessi, Elisabetta Bianchi, Marina Taliani, Licia Tomei, Andrea Urbani, Raffaele De Francesco, Frank Narjes
  • Patent number: 6197537
    Abstract: The present invention provides an assay for detecting and quantifying protease that is sensitive, rapid, and capable of screening numerous samples of small volume. Also provided by the present invention is a method for diagnosing disorders associated with connective tissue destruction in a subject by detecting and quantifying a particular protease in a biological sample. Further provided by the present invention is a method of detecting inhibitors of the activity of a protease by detecting primary amines that are exposed by the enzymatic degradation of a protease substrate.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: March 6, 2001
    Assignee: Long Island Jewish Medical Center
    Inventors: Srinivasa K. Rao, Leslie Kushner, Mahesh Mathrubutham, Jon R. Cohen
  • Patent number: 6197538
    Abstract: A method and apparatus for ascertaining and measuring the quality of milk by analyzing reflected or absorbed colors or both with which the milk is irradiated. The milk is thus irradiated with three colors of light in wavelengths of red, green and blue and the intensity and color of the light reflected by the milk or absorbed thereby, or both, is measured. The light sources are periodically switched off whereby the receiving sensors measure the same red, green and blue wavelengths due to background sources to the extent that they are reflected or absorbed or both by the milk. This data is then compared with data with the light sources switched on to produce the net data which is relevant to the milk as it is being received from the animal being milked.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: March 6, 2001
    Assignee: Maasland N.V. a Dutch Company
    Inventors: Karel van den Berg, Helena G. M. Vijverberg, Wilco van Lier
  • Patent number: 6197539
    Abstract: The invention is directed to novel methods of stabilizing blood compositions for use in the quality control of analytical techniques. The novel method comprises removing leucocytes from a blood composition to yield a depleted blood composition, stabilizing the leucocytes by treatment with an effective amount of a stabilizing agent comprising an aged transition metal solution, and then adding the resultant stabilized leucocytes to the depleted blood composition or a second blood component composition.
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: March 6, 2001
    Assignee: Northern General Hospital N.H.S. Trust
    Inventors: Vivian Granger, David Barnett, John T. Reilly, Petra S. M. Mayr
  • Patent number: 6197540
    Abstract: The invention is directed to novel stabilized blood compositions and methods of stabilizing blood compositions for use in the quality control of analytical techniques. The novel blood compositions comprise leucocytes and an effective amount of an aged transition metal solution. The novel method comprises removing leucocytes from a blood composition to yield a depleted blood composition, stabilizing the leucocytes by treatment with an effective amount of a stabilizing agent comprising an aged transition metal solution, and then, adding the resultant stabilized leucocytes to the depleted blood composition or a second blood component composition.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: March 6, 2001
    Assignee: Northern General Hospital N.H.S. Trust
    Inventors: Vivian Granger, David Barnett, John T. Reilly, Petra S. M. Mayr, Shawn P. Fay
  • Patent number: 6197541
    Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.
    Type: Grant
    Filed: February 17, 1993
    Date of Patent: March 6, 2001
    Assignees: COR Therapeutics, Inc., Regents of the University of California
    Inventor: Shaun R. Coughlin
  • Patent number: 6197542
    Abstract: The invention relates to genetic manipulations of eukaryotic organisms, with recombinant DNA comprising RNA virus derived sequences for protecting such organisms against RNA viruses or enabling inducible or tissue-specific production of foreign proteins/peptides or RNAs. One embodiment of the recombinant DNA according to the invention comprises recombinant DNA, comprising two, 12-1250 base pair long, inverted repeat nucleotide sequences with therebetween at least one nucleotide sequence which is derived from RNA virus which for its replication is dependent upon a viral RNA/RNA polymerase, said RNA virus derived sequence comprising at least cis elements for replication but no gene that codes for viral RNA/RNA polymerase and no gene that codes for viral coat protein. The invention also relates to eukaryotic or prokaryotic cells or organisms which incorporate the recombinant DNA according to the invention.
    Type: Grant
    Filed: July 28, 1997
    Date of Patent: March 6, 2001
    Assignee: Aveve, N.V.
    Inventors: Eddie Van Haute, Paul Ameloot, Jean De Lafonteyne, Walter Fiers
  • Patent number: 6197543
    Abstract: The invention provides three human vesicle membrane protein-like proteins (VMP) and polynucleotides which identify and encode VMP. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of VMP.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: March 6, 2001
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley, Preeti Lal, Purvi Shah
  • Patent number: 6197544
    Abstract: SBSEMVL polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilising SBSEMVL polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: March 6, 2001
    Assignee: SmithKline Beecham plc
    Inventors: David Michalovich, Philip David Hayes
  • Patent number: 6197545
    Abstract: The present invention provides a yeast cell comprising a nucleic acid functionally encoding a eukaryotic (e.g., mammalian) protein homologue of a subunit (Sec11p, Spc1p, Spc2p and/or Spc3p) of the yeast signal peptidase complex. The yeast cell of this invention can be, for example, of the genus Saccharomyces, Schizosaccharomyces, Pichia, Hansenula, Kluyveromyces and/or Yarrowia. Furthermore, the yeast cell can lack one or more functional subunits (Sec11p, Spc1p, Spc2p and/or Spc3p) of the yeast signal peptidase complex. The present invention further provides a method for producing a protein heterologous to a yeast cell comprising expressing, in the yeast cell of this invention, a nucleic acid functionally encoding the heterologous protein under conditions which permit the expression of the nucleic acid as a precursor protein having a signal peptide and processing of the precursor protein to a signal peptide-cleaved form of the protein.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: March 6, 2001
    Assignee: Vanderbilt University
    Inventors: Hong Fang, Neil Green, Luc Van Kaer
  • Patent number: 6197546
    Abstract: The invention provides PcrA Helicase polypeptides and polynucleotides encoding PcrA Helicase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing PcrA Helicase polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: March 6, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Damien McDevitt, Earl May, Annemarie St John, Stephanie Van Horn
  • Patent number: 6197547
    Abstract: An artificial operon comprising genes encoding each of a trigger factor, GroEL and GroES, an expression plasmid carrying the operon, an expression plasmid carrying a gene encoding the trigger factor, a cotransformant harboring an expression vector for a foreign protein and any one of the expression plasmids, and a method for producing a foreign protein comprising expressing a foreign protein by the use of the cotransformant, which are capable of expressing a foreign protein in a solubilized form and in a state of having a correct conformation.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: March 6, 2001
    Assignee: HSP Research Institute, Inc.
    Inventors: Kazuyo Sogo, Hideki Yanagi, Takashi Yura
  • Patent number: 6197548
    Abstract: Production of Bordetella pertactin antigens by expression in the methyltrophic yeast, Pichia; expression vectors containing DNA encoding the antigens and Pichia transformants containing the one of more copies of the DNA encoding a pertactin antigen.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 6, 2001
    Assignee: Medeva Pharma Limited
    Inventors: Jeffrey John Clare, Michael Anthony Romanos